NDA 020958 · Kenvue Brands
Pepcid Complete
Calcium Carbonate, Famotidine, Magnesium Hydroxide · Oral · Histamine-2 Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Oct 16, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
596
144 Phase 3, 25 recruiting
FAERS reports
2,416
816 serious, 74 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 25, 2026.
Use relieves heartburn associated with acid indigestion and sour stomach
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PEPCID COMPLETE · CALCIUM CARBONATE 800MG; FAMOTIDINE 10MG; MAGNESIUM HYDROXIDE 165MG · TABLET, CHEWABLE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbonate" as an intervention, any sponsor and status, largest first.
- A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00529373 · 16,071 participants · Start Sep 13, 2007 · Primary completion Nov 14, 2012
Drug: Odanacatib; Placebo for Odanacatib · For: Postmenopausal Osteoporosis
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- SAINT: Safe Induction of Labor TrialPivotal-lookingRecruiting
Oslo University HospitalAcademic, hospital or other
NCT05719467 · 3,000 participants (planned) · Start Jan 3, 2023 · Primary completion Jan 31, 2025
Drug: Buscopan 20 MG/ML Injectable Solution; Sodium bicarbonate and 2 more · For: Labor Complication; Induced; Birth; Pregnancy Related
Sites: Lørenskog, Norway; Oslo, Norway; Stavanger, Norway · 5 sites in all
- Vitamin D/Calcium Polyp Prevention StudyPivotal-lookingCompleted
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT00153816 · 2,813 participants · Start Jul 2004 · Primary completion Oct 2013
Drug: Calcium Carbonate; Vitamin D3 and 1 more · For: Colorectal Cancer; Polyps; Adenomas
Sites: Los Angeles, California; Denver, Colorado; Atlanta, Georgia · 11 sites in all
ShireTakeda (TAK)
NCT00160121 · 2,500 participants · Start Jan 10, 2005 · Primary completion Dec 13, 2005
Drug: Lanthanum carbonate · For: Kidney Failure, Chronic
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark StudyPivotal-lookingCompleted
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
NCT01578200 · 2,309 participants · Start Dec 24, 2011 · Primary completion Mar 25, 2019
Drug: Lanthanum Carbonate; Calcium Carbonate · For: Hemodialysis; Hyperphosphatemia
Sites: Shinagawa, Japan
- Sodium Bicarbonate in Cardiopulmonary ResuscitationPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01377337 · 2,130 participants (planned) · Start Dec 2011 · Primary completion Dec 2013
Drug: sodium bicarbonate · For: Sudden Cardiac Arrest
Sites: Haifa, Israel; Tel Aviv, Israel
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease483
- drug ineffective312
- acute kidney injury257
- renal failure174
- end stage renal disease133
- gastrooesophageal reflux disease133
- off label use100
- product use in unapproved indication100
- wrong technique in product usage process98
- incorrect dose administered97
- therapeutic response unexpected93
- product physical issue83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 9 |
| 2008 | 12 |
| 2009 | 37 |
| 2010 | 16 |
| 2011 | 18 |
| 2012 | 14 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 165 |
| 2016 | 150 |
| 2017 | 232 |
| 2018 | 254 |
| 2019 | 334 |
| 2020 | 208 |
| 2021 | 207 |
| 2022 | 143 |
| 2023 | 172 |
| 2024 | 110 |
| 2025 | 170 |
| 2026 | 134 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bone and vascular effects of magnesium supplements in CKD patients (the MagicalBone Pilot Study).
Pendón-Ruiz de Mier MV, Santamaría R, Moyano-Peregrín C, et al. · Nefrologia (Engl Ed) 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Lanthanum Carbonate on Blood Pressure in CKD.
Jamshidian MS, Larive B, Gassman J, et al. · Am J Kidney Dis 2021 · Letter, Randomized Controlled Trial
- Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.
Georgopoulos C, Duni A, Stamellou E, et al. · Hemodial Int 2025 · Systematic Review, Meta-Analysis
- Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Ginsberg C, Zelnick LR, Block GA, et al. · Nephrol Dial Transplant 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Cheng BR, Wu RY, Gao QY, et al. · Front Endocrinol (Lausanne) 2022 · Meta-Analysis, Systematic Review
- Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H, Fukagawa M, Hirakata H, et al. · JAMA 2021 · Comparative Study, Multicenter Study
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.